```html

X‑linked Thrombocytopenia

What is X‑linked thrombocytopenia?

X‑linked thrombocytopenia (XLT) is a hereditary bleeding disorder caused by mutations in the Wiskott‑Aldrich syndrome protein (WASP) gene that resides on the X chromosome. The defect leads to reduced numbers of platelets (thrombocytopenia) and often to abnormally small platelets. Because the gene is located on the X chromosome, the disease predominantly affects males; females are usually carriers and may have mild laboratory abnormalities but rarely develop clinically significant symptoms.

XLT is considered the milder end of the spectrum of Wiskott‑Aldrich syndrome (WAS). While classic WAS also includes eczema and severe immune deficiency, XLT patients typically have normal immune function and little or no eczema. Nonetheless, they remain at risk for infections, autoimmune disease, and, in a minority of cases, progression to full‑blown WAS or malignancy.

Common Causes

Although XLT itself is a genetic disorder, several other conditions can produce a similar pattern of low platelet count with small platelets and must be considered in the differential diagnosis.

• WASP gene mutations – the primary cause of XLT.
• Other X‑linked platelet disorders (e.g., X‑linked thrombocytopenia with/without dyserythropoiesis).
• Inherited MYH9‑related disorders – cause macrothrombocytopenia but can mimic XLT.
• Wiskott‑Aldrich syndrome (classic) – same gene, more severe immune and skin manifestations.
• Congenital amegakaryocytic thrombocytopenia (CAMT) – autosomal recessive, leads to absent megakaryocytes.
• Thrombocytopenia‑absent radius (TAR) syndrome – combines low platelets with absent radius bones.
• Autoimmune thrombocytopenia (ITP) – acquired, but must be ruled out especially in adolescents.
• Viral infections (e.g., HIV, hepatitis C, CMV) – can transiently lower platelet counts.
• Medications (e.g., quinine, heparin, certain antibiotics) – drug‑induced platelet destruction.
• Bone‑marrow infiltration (leukemia, lymphoma, myelodysplastic syndromes) – leads to pancytopenia.

Associated Symptoms

Patients with XLT often present with bleeding‑related complaints because platelets are essential for clot formation.

• Easy bruising (purpura) on the arms, legs, or trunk.
• Nosebleeds (epistaxis) that are frequent or prolonged.
• Bleeding gums, especially after brushing or dental work.
• Prolonged bleeding from minor cuts or scrapes.
• Heavy menstrual periods (menorrhagia) in adolescent males assigned female at birth or female carriers.
• Petechiae – tiny red or purple spots on the skin, often on the lower legs.
• Occasional gastrointestinal bleeding presenting as melena or hematochezia.
• Rarely, intracranial hemorrhage, especially after head trauma.

Because XLT usually spares the immune system, systemic signs such as fever, recurrent infections, or eczema are not typical, helping separate it from classic WAS.

When to See a Doctor

Any of the following should prompt an earlier medical evaluation:

• Unexplained bruising or petechiae, especially if spreading or increasing.
• Bleeding that does not stop after applying pressure for more than 10 minutes.
• Frequent nosebleeds (more than once a week) or bleeding that requires medical attention.
• Bleeding after minor injuries, dental procedures, or circumcision.
• Dark stools, vomiting blood, or blood in the urine.
• Signs of anemia (fatigue, pallor, shortness of breath) that develop alongside low platelets.
• Family history of X‑linked bleeding disorders or unexplained deaths from bleeding.

Diagnosis

Diagnosing XLT involves a stepwise approach that combines clinical assessment, laboratory testing, and genetic confirmation.

1. Detailed medical and family history

Clinicians ask about bleeding episodes, previous surgeries, medication use, and any male relatives with similar problems.

2. Complete blood count (CBC) with platelet indices

• Platelet count typically 20,000–70,000 µL (normal 150,000–450,000 µL).
• Mean platelet volume (MPV) is low, reflecting small platelets.

3. Peripheral blood smear

Microscopic examination confirms small platelets and rules out platelet clumping or abnormal cell morphology.

4. Bone‑marrow aspirate/biopsy (selected cases)

Used when the cause is unclear; XLT shows normal or mildly decreased megakaryocytes with normal maturation.

5. Immunologic work‑up (if immune deficiency is suspected)

Quantitative immunoglobulins, vaccine response testing, and lymphocyte subset analysis help differentiate XLT from classic WAS.

6. Genetic testing

Sequencing of the WASP gene identifies pathogenic variants in >90 % of confirmed XLT cases. This test also provides definitive carrier status for female relatives.

7. Additional labs to exclude secondary causes

• Viral serologies (HIV, hepatitis B/C, CMV).
• Coagulation profile (PT/INR, aPTT) – usually normal in XLT.
• Autoimmune panel (ANA, anti‑platelet antibodies) if immune thrombocytopenia is considered.

Guidelines from the CDC and NIH recommend confirming the diagnosis with genetic testing whenever possible.

Treatment Options

Treatment aims to raise platelet counts enough to prevent bleeding, address any complications, and improve quality of life.

1. Observation

Children with platelet counts >30,000 µL and no significant bleeding may simply be monitored with regular CBCs.

2. Platelet‑transfusion support

• Indicated for active bleeding, before surgery, or when counts drop < 20,000 µL.
• Transfusion frequency varies; over‑use can lead to alloimmunization.

3. Pharmacologic therapies

• Intravenous immune globulin (IVIG) – useful for short‑term rise in platelets, especially before procedures.
• Tranexamic acid (oral, topical, or IV) – antifibrinolytic agent that helps control mucosal bleeding (e.g., nosebleeds, dental work).
• Thrombopoietin receptor agonists (eltrombopag, romiplostim) – have been explored in refractory XLT; data are limited but may be an option under specialist care.
• Immunosuppressants are generally not indicated because the problem is not immune‑mediated.

4. Curative approaches

• Hematopoietic stem‑cell transplantation (HSCT) – the only potential cure. Indicated for severe thrombocytopenia, progressive disease, or evolution to classic WAS. Requires an HLA‑matched donor (sibling or unrelated). Risks include graft‑versus‑host disease and infection.
• Gene therapy – experimental; early‑phase trials using lentiviral vectors to deliver a functional WASP gene are ongoing (see recent data from the Nature Medicine 2023 trial).

5. Supportive/home measures

• Avoid NSAIDs and aspirin, which impair platelet function.
• Use soft toothbrushes and gentle flossing to reduce gum bleeding.
• Apply a humidifier in dry climates to lessen nasal mucosa dryness.
• Wear protective gear (helmets, padded clothing) during sports to minimize trauma.
• Maintain up‑to‑date immunizations (especially pneumococcal and influenza) to prevent infections that could exacerbate bleeding.

Prevention Tips

While a genetic condition cannot be “prevented,” several strategies can reduce bleeding episodes and improve overall health.

• Family counseling – Genetic counseling helps carriers understand reproductive options (prenatal testing, pre‑implantation genetic diagnosis).
• Regular monitoring – Quarterly CBCs in childhood, semi‑annual in adulthood, or sooner after any bleeding event.
• Medication review – Discuss all over‑the‑counter drugs and supplements with a clinician; avoid agents that impair platelet function.
• Injury avoidance – Use protective equipment, avoid high‑impact activities that may cause head trauma.
• Prompt treatment of infections – Fever or viral illness can temporarily lower platelet counts; early antiviral or antibiotic therapy may lessen impact.
• Vaccination – Influenza, COVID‑19, and other routine vaccines lower the risk of severe infections that could precipitate bleeding.
• Healthy diet – Adequate vitamin K (leafy greens) and folate support normal clotting pathways, though they do not directly raise platelet counts.

Emergency Warning Signs

Key Take‑aways

X‑linked thrombocytopenia is a rare, X‑chromosome‑linked disorder that leads to low‑count, small platelets and a propensity for bleeding. While many patients can be managed with observation, occasional transfusions, and avoidance of platelet‑impairing drugs, severe cases may require curative stem‑cell transplantation or experimental gene therapy. Early recognition of bleeding, routine laboratory monitoring, and genetic counseling for families are essential components of care.

For the most up‑to‑date recommendations, refer to reputable sources such as the Mayo Clinic, CDC, and the NIH.

```